drugset / Trial / NCT00045422
Interferon Alfa and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
Open-labelTreatment
Summary
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. Combining interferon alfa with imatinib mesylate may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combining interferon alfa with imatinib mesylate in treating patients who have chronic myelogenous leukemia.
Timeline
- Start
- 2002-04
- Primary completion
- 2003-10
- Completion
- 2003-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Imatinib | Small molecule | — | Oral |
| Subject | interferon alfa-2b | Protein / enzyme biologic | — | Subcutaneous |